For years, KRAS-mutant lung cancer has been one of oncology's most frustrating targets. While KRASG12C inhibitors transformed care for one mutation subtype, patients harboring codon 13 variants have had no equivalent precision option — until now. This gap matters because codon 13 mutations represent a meaningful fraction of KRAS-driven non-small cell lung cancer (NSCLC), and their distinct biology has largely been uncharacterized at therapeutic depth.
Working across a large multinational NSCLC cohort paired with preclinical models, investigators systematically mapped the tumorigenic landscape of KRASG13X mutations. A striking finding emerged: KRASG13C and KRASG13D confer reduced oncopotency compared to codon 12 counterparts — particularly KRASG13C — suggesting these tumors may be biologically less aggressive but still clinically significant. The team catalogued functionally important co-mutations including KEAP1, STK11, BRAF, and NF1, which are known to influence treatment response and prognosis. Critically, a novel RAS(ON) G13C-selective inhibitor, RMC-8839, demonstrated meaningful viability reduction across KRASG13C cell line panels. A drug repurposing screen further identified selective chemotherapy vulnerability in this subtype, leading to the combination of RMC-8839 with docetaxel — which showed robust anti-proliferative activity both in vitro and in vivo.
This work is potentially paradigm-shifting for a neglected patient subgroup. The RAS(ON) inhibitor class — which targets the active, GTP-bound form of mutant RAS rather than the inactive GDP-bound state — represents a mechanistically distinct approach from first-generation KRASG12C inhibitors like sotorasib. The reduced oncopotency of KRASG13C relative to KRASG12C adds a nuanced layer: these tumors may be more tractable therapeutically. However, the findings remain preclinical for the combination strategy, and translation to patient outcomes requires well-designed clinical trials. The co-mutation landscape, particularly KEAP1 and STK11 loss, may predict which patients benefit least, an important stratification question for future studies. Overall, this is among the most mechanistically grounded early-phase work on codon 13 KRAS biology published to date.